Micro-Medicines Target Brain Diseases

Researchers at the University of Essex, collaborating internationally, have engineered microscopic medicines capable of working directly inside human cells. These novel antibody fragments, termed intrabodies, were created using artificial intelligence and are designed to target specific proteins associated with neurodegenerative diseases such as Alzheimer's, Parkinson's, and motor neurone disease (MND).

The key innovation lies in redesigning antibody fragments to be stable and functional within the cellular environment, unlike conventional antibodies that operate outside cells. This was achieved by understanding the crucial role of electrical charge in intrabody stability. The findings could unlock new therapeutic strategies for millions affected by these debilitating conditions.

This advance holds significant promise for repurposing millions of previously developed antibodies, turning them into powerful tools for research and potential treatments. The research, funded by the MND Association, aims to combat diseases currently without cures and presents a major challenge in medicine discovery.

The redesigned molecules will be made freely available to the scientific community, fostering further exploration into novel therapeutic avenues for neurodegenerative disorders.